Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Operating Leases: 2022-2024

Historic Operating Leases for Altimmune (ALT) over the last 3 years, with Dec 2024 value amounting to $1.4 million.

  • Altimmune's Operating Leases fell 16.92% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 16.92%. This contributed to the annual value of $1.4 million for FY2024, which is 701.14% up from last year.
  • As of FY2024, Altimmune's Operating Leases stood at $1.4 million, which was up 701.14% from $175,000 recorded in FY2023.
  • Altimmune's 5-year Operating Leases high stood at $1.4 million for FY2024, and its period low was $175,000 during FY2023.
  • Its 3-year average for Operating Leases is $749,667, with a median of $672,000 in 2022.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 73.96% in 2023, then soared by 701.14% in 2024.
  • Altimmune's Operating Leases (Yearly) stood at $672,000 in 2022, then crashed by 73.96% to $175,000 in 2023, then skyrocketed by 701.14% to $1.4 million in 2024.